NCT07390045 (ECO 2) is a NA clinical trial of EXCAP in Cancer, sponsored by University of Rochester.

Who is sponsoring NCT07390045?

NCT07390045 is sponsored by University of Rochester.

What drugs are being tested in NCT07390045?

Interventions in NCT07390045: EXCAP, MAAT, ECO.

Is NCT07390045 still recruiting?

NCT07390045 is currently recruiting now. Last updated 7 April 2026.

Last reviewed 2026-04-07 · How we verify

NCT07390045: ECO 2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors

Recruiting now NA Last updated 7 April 2026

What this trial tests

NA trial testing EXCAP in Cancer in 40 participants. Currently enrolling.

Timeline

1 May 2026

Primary endpoint
31 March 2028

31 March 2028

Quick facts

Lead sponsor	University of Rochester
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	40
Start date	1 May 2026
Primary completion	31 March 2028
Estimated completion	31 March 2028
Sites	1 location across United States

Drugs / interventions tested

EXCAP
MAAT
ECO

Conditions studied

Cancer — all drugs for Cancer →

Sponsor

University of Rochester

Who can join

65 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to assess the preliminary effects of an integrated exercise and cognitive rehabilitation intervention (ECO), an exercise intervention (EXCAP), and a cognitive rehabilitation intervention (MAAT) as compared to usual care on objective cognition (Trail Making Test).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting
NCT06807593 — Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients · Phase 2 · recruiting

Other University of Rochester trials

Trials by the same sponsor.

NCT07075965 — Calcium Channel Blocker in Myotonic Dystrophy Type 1 · Phase 1 · not yet recruiting
NCT07423104 — A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloi · Phase 2 · not yet recruiting
NCT05744869 — SBAT for Health Equity · NA · not yet recruiting
NCT06052956 — Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses · Phase 2 · not yet recruiting
NCT07032636 — Reducing Crises and Suicide Within the Idaho Army National Guard · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07390045 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Rochester
Last refreshed: 7 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07390045.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing